| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_640dd506847c5150940a6d9b95a41a3d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20222 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-766
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-766 |
| filingDate |
2019-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9454d3a2fac8ac27f4b63c2000eada4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b255c8d899d3fb04bafea0631c052762 |
| publicationDate |
2020-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020233102-A1 |
| titleOfInvention |
Pharmaceutical composition for treatment of tumor or cancer, and application thereof |
| abstract |
Provided are a pharmaceutical composition for treatment of a tumor or cancer, and an application thereof. The pharmaceutical composition comprises an oncolytic rhabdovirus and a CD38 small molecule inhibitor such as rhein by means of direct local injection or systemic administration or intratumoral delivery. The oncolytic rhabdovirus has the property of recognizing tumor cells and would not cause damage to normal cells; moreover, the CD38 small molecule inhibitor can specifically inhibit the activity of T-cell receptor molecules; the use of the oncolytic rhabdovirus and the CD38 small molecule inhibitor in combination has significant advantages in safety and efficacy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023078574-A1 |
| priorityDate |
2019-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |